Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Holger Scheible, Marc Laisney, Elmar Wimmer, Ana Javornik & Hugues Dolgos. (2013) Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica 43:12, pages 1084-1094.
Read now
Read now
Darren S Sigal & Alan Saven. (2008) Cladribine in indolent non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 8:4, pages 535-545.
Read now
Read now
W. N. Wu, L. A. Mckown, M. D. Moyer & W. Cheung. (2004) Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin®) in animals and humans. Xenobiotica 34:6, pages 591-606.
Read now
Read now
Tadeusz Robak. (2003) Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias. Leukemia & Lymphoma 44:3, pages 391-409.
Read now
Read now
Stephen A Johnson. (2001) Nucleoside analogues in the treatment of haematological malignancies. Expert Opinion on Pharmacotherapy 2:6, pages 929-943.
Read now
Read now
Eric Van Den Neste, Andre Delannoy, Walter Feremans, Augustin Ferrant & Lucienne Michaux. (2001) Second Primary Tumors and Immune Phenomena After Fludarabine or 2-Chloro-2′-Deoxy adenosine Treatment. Leukemia & Lymphoma 40:5-6, pages 541-550.
Read now
Read now
Scott A. Tetreault & Alan Saven. (2000) Delayed Onset of Autoimmune Hemolytic Anemia Complicating Cladribine Therapy for Waldenström Macroglobulinemia. Leukemia & Lymphoma 37:1-2, pages 125-130.
Read now
Read now
Wendy P. Gatiac, Alan R.P. Patersona, Andrew R. Belch, Vera Chlumecky, Loree M. Larratt, Michael J. Mant & A. Robert Turner. (1998) Es Nucleoside Transporter Content of Acute Leukemia Cells: Role in Cell Sensitivity to Cytarabine (araC). Leukemia & Lymphoma 32:1-2, pages 45-54.
Read now
Read now
T. Robak, J. Gora-Tybor, E. Krykowski, J. A. Walewski, A. Borawska, A. Plubańska, P. Potemski, A. Hellmann, J. M. Zaucha, L. Konopka, B. Ceglarek, T. Durýński, A. Sikorska, K. Michalak, J. Urasiński, J. Opalińska, A. Dmoszyńska, M. B. Adamczyk-Cioch, Z. Kuratowska, J. Dwilewicz-Trojaczek, P. Boguradzki, M. Dere, S. May & P. Grieb. (1997) Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma. Leukemia & Lymphoma 26:1-2, pages 99-105.
Read now
Read now
Aaron Polliack. (1997) Hairy Cell Leukemia and Allied Chronic Lymphoid Leukemias: Current Knowledge and New Therapeutic Options. Leukemia & Lymphoma 26:sup1, pages 41-51.
Read now
Read now
K. Warzocha, E. Krykowski, J. Góra-tybor, A. Fronczak & T. Robak. (1996) Fulminant 2-Chlorodeoxyadenosine-Related Peripheral Neuropathy in a Patient with Paraneoplastic Neurological Syndrome Associated with Lymphoma. Leukemia & Lymphoma 21:3-4, pages 343-346.
Read now
Read now
M. J. Keating, S. O'brien, H. Kantarjian, L. B. Robertson, C. Koller, M. Beran & E. Estey. (1993) Nucleoside Analogs in Treatment of Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 10:sup1, pages 139-145.
Read now
Read now
F. Lauria, D. Benfenati, D. Raspadori, D. Rondelli, P. L. Zinzani & S. Tura. (1993) High Complete Remission Rate in Hairy Cell Leukemia Treated with 2-Chlorodeoxyadenosine. Leukemia & Lymphoma 11:5-6, pages 399-404.
Read now
Read now
M. A. Dimopoulos, S. O'brien, H. Kantarjian, E. E. Estey, M. J. Keating & R. Alexanian. (1993) Treatment of Waldenstrom's Macroglobulinemia with Nucleoside Analogues. Leukemia & Lymphoma 11:sup2, pages 105-108.
Read now
Read now
Alan Saven & Lawrence D. Piro. (1993) 2-Chlorodeoxyadenosine in the Treatment of Hairy Cell Leukemia. Cancer Investigation 11:5, pages 559-564.
Read now
Read now
Articles from other publishers (50)
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
7
159
.
Ayman Qasrawi, Waled Bahaj, Lien Qasrawi, Omar Abughanimeh, John Foxworth & Rakesh Gaur. (2018) Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?. Annals of Hematology 98:3, pages 561-579.
Crossref
Crossref
Elise Anderes & Sucha Nand. 2014. Neurologic Aspects of Systemic Disease Part II. Neurologic Aspects of Systemic Disease Part II
1125
1139
.
Jerzy Z. Blonski, Tadeusz Robak, Krzysztof Chojnowski, Joanna Gora‐Tybor, Krzysztof Warzocha, Bernadetta Ceglarek, Ilona Seferynska, Malgorzata Calbecka, Aleksandra Kostyra, Beata Stella‐Holowiecka, Janusz Kloczko, Anna Dmoszynska, Malgorzata Kowal, Krzysztof Lewandowski, Jadwiga Dwilewicz‐Trojaczek, Elzbieta Wiater, Kazimierz Kuliczkowski, Stanislaw Potoczek, Andrzej Hellmann, Andrzej Mital, Aleksander Skotnicki, Wieslaw Nowak, Kazimierz Sulek, Krystyna Zawilska & Jacek Trelinski. (2013)
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine‐based regiments or chlorambucil – follow‐up of
PALG
‐
CLL
randomized trials
. European Journal of Haematology 91:1, pages 1-9.
Crossref
Crossref
Jean-François Morère, Françoise Mornex & Denis SoulièresS. Castaigne. 2011. Thérapeutique du cancer. Thérapeutique du cancer
837
846
.
Harvey M. Golomb. (2008) Hairy Cell Leukemia: Treatment Successes in the Past 25 Years. Journal of Clinical Oncology 26:16, pages 2607-2609.
Crossref
Crossref
Grant R Goodman, Ernest Beutler & Alan Saven. (2003) Cladribine in the treatment of hairy-cell leukaemia. Best Practice & Research Clinical Haematology 16:1, pages 101-116.
Crossref
Crossref
H. M. Golomb. 2003. Oncologic Therapies. Oncologic Therapies
263
267
.
Marco Montillo, Alessandra Tedeschi, Susan O'Brien, Francesco Di Raimondo, Susan Lerner, Alessandra Ferrajoli, Enrica Morra & Michael J. Keating. (2002) Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97:1, pages 114-120.
Crossref
Crossref
Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, Maria N. Dimopoulou, Marina P. Siakantaris, Flora N. Kontopidou & Maria K. Angelopoulou. (2002) B‐chronic lymphocytic leukemia: practical aspects. Hematological Oncology 20:3, pages 103-146.
Crossref
Crossref
Kenneth R. Hande. 2002. Encyclopedia of Cancer. Encyclopedia of Cancer
515
525
.
Stephen A. Johnson. (2000) Clinical Pharmacokinetics of Nucleoside Analogues. Clinical Pharmacokinetics 39:1, pages 5-26.
Crossref
Crossref
George P. A. RiceMassimo FilippiGiancarlo Comi. (2000) Cladribine and progressive MS. Neurology 54:5, pages 1145-1155.
Crossref
Crossref
H. M. Golomb. 1999. Oncologic Therapies. Oncologic Therapies
411
418
.
M.A Fridrik, G Jäger, H.R Kienzer, H Hausmaninger, P Oppitz, O Krieger, A Zabernigg, A Lang, M Neubauer, G Weidinger, L Schiller, H.L Seewann, A Chott & W Linkesch. (1998) Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma. European Journal of Cancer 34:10, pages 1560-1564.
Crossref
Crossref
T Robak, M Błasińska-Morawiec, J.Z Błoński, E Krykowski, M Komarnicki, E Trepińska, M Kaźmierczuk, J Hansz, A Dmoszyńska, J Roliński, L Konopka, A.B Skotnicki, W.S Nowak, S Kotlarek-Haus, B Zdziarska & I Urasiński. (1997) The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. European Journal of Cancer 33:14, pages 2347-2351.
Crossref
Crossref
Kimo C. Stine, Robert L. Saylors, Laura L. Williams & David L. Becton. (1997) 2-chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Medical and Pediatric Oncology 29:4, pages 288-292.
Crossref
Crossref
Ashley K Morris, Jill M Kolesar & John G Kuhn. (2016) Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine. Journal of Oncology Pharmacy Practice 3:2, pages 94-109.
Crossref
Crossref
T. Robak, M. Błasińska‐Morawiec, E. Krykowski, A. Hellmann & L. Konopka. (2009) Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2‐chlorodeoxyadenosine (cladribine). European Journal of Haematology 58:2, pages 109-113.
Crossref
Crossref
Alan Saven & Lawrence D. Piro. 1996. Advances in Lymphoma Research. Advances in Lymphoma Research
15
26
.
A. Delannoy. (1996) 2-Chloro-2′-deoxyadenosine: clinical applications in hematology. Blood Reviews 10:3, pages 148-166.
Crossref
Crossref
JC Sipe, JS Romine, JA Koziol, R McMillan, J Zyroff & E Beutler. (2016) Development of cladribine treatment in multiple sclerosis. Multiple Sclerosis Journal 1:6, pages 343-347.
Crossref
Crossref
S.A. Johnson. (1996) Purine analogues in the management of lymphoproliferative diseases. Clinical Oncology 8:5, pages 289-296.
Crossref
Crossref
Jack C. Sipe, J. S. Romine, J. Zyroff, J. Koziol & E. Beutler. 1996. Multiple Sclerosis. Multiple Sclerosis
313
334
.
Henrik Depenbrock, Martin Wenger, Robert Peter, Christian Fellbaum, Thomas Block, Johannes Rastetter & Axel -R. Hanauske. (1995) Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming unitsin vitro. Investigational New Drugs 13:2, pages 117-123.
Crossref
Crossref
C. Pott-Hoeck & W. Hiddemann. (1995) Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Annals of Oncology 6:5, pages 421-433.
Crossref
Crossref
Viera Reichelov�, Gunnar Juliusson, Tatiana Spasokoukotskaja, Staffan Eriksson & Jan Liliemark. (1995) Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2?-deoxyadenosine. Cancer Chemotherapy and Pharmacology 36:6, pages 524-529.
Crossref
Crossref
H. -J. Guchelaar, D. J. Richel & M. R. Schaafsma. (1994) Clinical and toxicological aspects of the antineoplastic drug cladribine: A review. Annals of Hematology 69:5, pages 223-230.
Crossref
Crossref
Harvey M. Golomb. (1994) Do we know the treatment of choice for hairy cell leukemia?. Annals of Oncology 5:8, pages 676-677.
Crossref
Crossref
A. Delannoy, A. Ferrant, P. Martiat, A. Bosly & J.L. Michaux. (2009) 2‐chlorodeoxyadenosine and multiple myeloma. European Journal of Haematology 53:3, pages 181-182.
Crossref
Crossref
Monika Lechleitner, Bernhard Auer, Udo Zilian, Fritz Hoppichler, Michael Schirmer, Bernhard Föger, Francoise Geisen, Josef R. Patsch & Günther Konwalinka. (1994) The immunosuppressive substance 2-chloro-2-deoxyadenosine modulates lipoprotein metabolism in a murine macrophage cell line (P388 cells). Lipids 29:9, pages 627-633.
Crossref
Crossref
Ken Kobayashi, Nicholas J. Vogelzang, Sheila M. O'Brien, Richard L. Schilsky, Everett E. Vokes & Mark J. Ratain. (1994) A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer 74:1, pages 168-173.
Crossref
Crossref
Alan Saven, Lawrence D. Piro, Robert H. Lemon, Michael L. Figueroa, Michael Kosty, Douglas J. Ellison & Ernest Beutler. (1994) Complete hematologic remissions in chronic-phase, philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73:12, pages 2953-2963.
Crossref
Crossref
Carlos J. Carrera, Alan Saven & Lawrence D. Piro. (1994) Purine Metabolism of Lymphocytes: Targets for Chemotherapy Drug Development. Hematology/Oncology Clinics of North America 8:2, pages 357-381.
Crossref
Crossref
Alastair J.J. Wood, Alan Saven & Lawrence Piro. (1994) Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia. New England Journal of Medicine 330:10, pages 691-697.
Crossref
Crossref
F. Lauria, D. Rondelli, D. Raspadori, D. Benfenati & S. Tura. (2009) Rapid restoration of natural killer activity following treatment with 2‐chlorodeoxyadenosine in 22 patients with hairy‐cell leukemia. European Journal of Haematology 52:1, pages 16-20.
Crossref
Crossref
D.C. Betticher, M.F. Fey, A. von Rohr, A. Tobler, H. Jenzer, A. Gratwohl, A. Lohri, P. Pugin, U. Hess, O. Pagani, G. Zulian & T. Cerny. (1994) High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Annals of Oncology 5:1, pages 57-64.
Crossref
Crossref
Maurizio Tonato & Anna Maria Mosconi. 1994. Innovative Antimetabolites in Solid Tumours. Innovative Antimetabolites in Solid Tumours
53
59
.
Alan Saven & Lawrence D. Piro. (1993) The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies. Cancer 72:S11, pages 3470-3483.
Crossref
Crossref
D.C. Betticher, M.F. Fey, M. Rabaglio, T. Cerny, U. Hess, V. Meier, M. Stalder & G. Zulian. (1993) Cladribine and severe myelotoxicity. The Lancet 342:8883, pages 1369.
Crossref
Crossref
Alan Saven, Michael L. Figueroa, Lawrence D. Piro & Joseph D. Rosenblatt. (1993) 2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis X. New England Journal of Medicine 329:10, pages 734-735.
Crossref
Crossref
P. L. Zinzani, F. Lauria, D. Rondelli, D. Benfenati, D. Raspadori, M. Bocchia, A. Gozzetti, M. Cavo, T. M. Cirio, F. Zaja, D. Russo, R. Fanin, P. Galieni, R. Algeri, M. Fiacchini & S. Tura. (2009) Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia. European Journal of Haematology 51:2, pages 93-97.
Crossref
Crossref
M. Ryba, P. Grieb, M. Pastuszko, J. Bidziński, J. Andrychowski, C. Dziewiecki, P. Bojarski & L. Królicki. (1993) Successful prevention of neurological deficit in SAH patients with 2-chlorodeoxyadenosine. Acta Neurochirurgica 124:2-4, pages 61-65.
Crossref
Crossref
Michael J. Keating. (1993) Immunosuppression with purine analogues — the flip side of the gold coin. Annals of Oncology 4:5, pages 347-348.
Crossref
Crossref
M. Ryba, P. Grieb, M. Walski, J. Sawicki & M. Pastuszko. (1993) 2-Chloro-2? deoxyadenosine prevents angiopathic changes in cerebral arteries in experimental SAH in rabbits. Acta Neurochirurgica 122:1-2, pages 118-121.
Crossref
Crossref
S. P. Mulligan & D. Catovsky. (2008) The chronic B‐cell leukaemias. Australian and New Zealand Journal of Medicine 23:1, pages 42-50.
Crossref
Crossref
Alan Saven, Lawrence D. Piro, Carlos J. Carrera, Dennis A. Carson & Ernest Beutler. 1993. Leukemia: Advances in Research and Treatment. Leukemia: Advances in Research and Treatment
15
34
.
Gunnar Juliusson, Annika Elmhorn-Rosenborg & Jan Liliemark. (1992) Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to Fludarabine. New England Journal of Medicine 327:15, pages 1056-1061.
Crossref
Crossref
E Beutler. (1992) Cladribine (2-chlorodeoxyadenosine). The Lancet 340:8825, pages 952-956.
Crossref
Crossref
AYALEW TEFFERI & ROBERT L. PHYLIKY. (1992) A Clinical Update on Chronic Lymphocytic Leukemia. II. Critical Analysis of Current Chemotherapeutic Modalities. Mayo Clinic Proceedings 67:5, pages 457-461.
Crossref
Crossref